181  0 Kommentare Ligandal Is Developing Potential Antidote And Vaccine To SARS-CoV-2 - Seite 2

In the present instance, the company is reprogramming the viral binding elements of SARS-CoV-2 ("COVID") to no longer afford a "cloak" for this sophisticated immune-shielded virus.  It also offsets the need for alternative therapeutic solutions because the peptide scaffolds will expose the virus for the host's own immune system to learn and deal with. This approach is fully synthetic, which lends itself to rapid prototyping and personalized approaches for various viruses.  It can also scale-up on the order of days or weeks instead of years. 

"Ligandal's goal is to make lifecare available for all, and affordable for all," stated Eric Greenberg, member of Ligandal's board of directors. "Today's systems are not optimized for our current technology and understanding of the human genome.  They weren't engineered from scratch with today's knowledge.  As I foreshadowed in 2003 in the Acumen Journal of Life Sciences, where I was Chairman and CEO, I warned the world of bio-warfare and asked if we were prepared.  Medicine must rethink traditional approaches if we are to rapidly respond to threats from new generations of pathogens, whether they crossed species or were bioengineered. It is our opinion that COVID is also a neurological virus.  We are seeing today how rapidly these pathogens can spread and impact both respiratory and neurological systems, putting entire communities at risk.  That's why Ligandal is aggressively pursuing treatment strategies that can rapidly adapt to any form of viral attack and/or infection." 

Immunity and Protection Challenges

Current approaches of developing vaccines and allopathic treatments may not provide adequate protection against this virus, given the virus' sophisticated immune cloaking mechanisms whereby the virus forms a coating in soluble ACE2, which is also present upon the cell membrane as a viral-entry mechanism. However, this soluble ACE2 is hypothesized to act as a shield against antibody binding sites on the virus' spike protein, which would effectively cloak the virus from adaptive immune recognition. 

Lesen Sie auch

Q1-Zahlen überzeugen

Mehr Snacks, Säfte und Limos: Pepsico übertrifft die Erwartungen

vor 18 Minuten

Vor wichtigen Earnings

Techaktien zeigen Anzeichen eines Zusammenbruchs – größter Crash seit 4 Jahren

vor 56 Minuten

100 Mrd. US-Dollar verbrannt

TSMC im Bann der Bären: Anleger wetten auf einen weiteren Crash der Aktie

vor 1 Stunde

Cashflow-/Bilanzangst

Tesla vor brutalem Quartal: "… dann ist die Aktie am Ende" – was erwartet wird!

heute 10:46

This, coupled with the virus' other mechanisms for burying antibody immune-epitope sites, poses a significant problem in eliminating the virus from the body. Ligandal's peptide scaffolds are designed to be ultra-high-affinity, fully-synthetic constructs that can serve as competitive displacers to the viral entry mechanisms, as well as preventing ACE2 from forming its cloak around the virus. Furthermore, the scaffolds are designed to act as immune boosters, presenting precise antibody immuno-epitopes as well as T-cell receptor (TCR) immuno-epitopes against the key viral immunogenic sites.